Spruce Biosciences Inc (SPRB)
$0.7
Insights on Spruce Biosciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 118.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 335.4%
Performance
- $0.70$0.71$0.70
0.33%
Downside
Day's Volatility :1.75%
Upside
1.42%
- $0.67$5.95$0.70
4.13%
Downside
52 Weeks Volatility :88.72%
Upside
88.24%
Returns
| Period | Spruce Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -79.38% | 0.5% | 0.0% |
6 Months | -34.49% | 11.7% | 0.0% |
1 Year | -66.3% | 6.2% | 2.2% |
3 Years | -95.89% | 13.5% | -23.0% |
Highlights
Market Capitalization | 28.9M |
Book Value | $1.87 |
Earnings Per Share (EPS) | -1.24 |
Wall Street Target Price | 2.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -386.7% |
Return On Assets TTM | -34.28% |
Return On Equity TTM | -66.1% |
Revenue TTM | 10.1M |
Revenue Per Share TTM | 0.26 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -51.9M |
Diluted Eps TTM | -1.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.12 |
EPS Estimate Next Year | -1.01 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 292.86%
Technicals Summary
Sell
Neutral
Buy
Spruce Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Spruce Biosciences Inc | 0.14% | -34.49% | -66.3% | -95.89% | -95.88% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Spruce Biosciences Inc | NA | NA | NA | -1.12 | -0.66 | -0.34 | NA | 1.87 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Spruce Biosciences Inc | Buy | $28.9M | -95.88% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Novo A/S
16.51%RiverVest Venture Management LLC
7.21%The Carlyle Group Inc
7.11%Rock Springs Capital Management LP
6.41%5AM Venture Management, LLC
5.81%Armistice Capital, LLC
5.48%
Corporate Announcements
Spruce Biosciences Inc Earnings
Spruce Biosciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.
Organization | Spruce Biosciences Inc |
Employees | 29 |
CEO | Mr. Michael G. Grey |
Industry | Commercial Services |
